CE-158
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
CE-158 is an atypical dopamine reuptake inhibitor (DRI) that was derived from modafinil. It is often but not always referred to as the enantiopure enantiomer (S,S)-CE-158 instead. CE-158 is a highly selective DRI with much greater potency than modafinil. As (S,S)-CE-158, its inhibitory potencies ( ) at the monoamine transporters are 227 nM at the dopamine transporter (DAT), 11,970 nM at the norepinephrine transporter (NET) (53-fold lower), and inactive at the serotonin transporter (SERT). The drug shows pro-motivational effects in animals and reverses tetrabenazine-induced motivational deficits. It increases dopamine levels in the nucleus accumbens, blocks amphetamine-induced dopamine release in vitro, shows no effect on locomotor activity with acute or repeated administration except at a high dose, and enhances learning in animals. CE-158 was first described by 2020. It is closely related to CE-123, an earlier modafinil analogue. CE-158 and related agents are of interest in the potential treatment of motivational disorders, psychostimulant use disorder (PSUD), and Alzheimer's disease.
CE-158 is an atypical dopamine reuptake inhibitor (DRI) that was derived from modafinil. It is often but not always referred to as the enantiopure enantiomer (S,S)-CE-158 instead. CE-158 is a highly selective DRI with much greater potency than modafinil. As (S,S)-CE-158, its inhibitory potencies ( ) at the monoamine transporters are 227 nM at the dopamine transporter (DAT), 11,970 nM at the norepinephrine transporter (NET) (53-fold lower), and inactive at the serotonin transporter (SERT). The drug shows pro-motivational effects in animals and reverses tetrabenazine-induced motivational deficits. It increases dopamine levels in the nucleus accumbens, blocks amphetamine-induced dopamine release in vitro, shows no effect on locomotor activity with acute or repeated administration except at a high dose, and enhances learning in animals. CE-158 was first described by 2020. It is closely related to CE-123, an earlier modafinil analogue. CE-158 and related agents are of interest in the potential treatment of motivational disorders, psychostimulant use disorder (PSUD), and Alzheimer's disease.
See also
List of modafinil analogues and derivatives MRZ-9547 PRX-14040
References
Text derived from https://en.wikipedia.org/w/index.php?oldid=1328675890 under CC BY-SA 4.0; modifications have been made.